Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer
A Randomized, Single-blind, Placebo-controlled, Multicentre Study to Evaluate the Effect of Risedronate and Placebo on Bone Mineral Density in Men Undergoing Androgen Deprivation Therapy With Leuprolide Acetate
  • Phase

    Phase 3
  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    risedronate ...
  • Study Participants

Prostate cancer patients treated with LHRH agonists (e.g., leuprolide) lose bone mineral density. This is similar to post-menopausal osteoporosis. Risedronate is approved to prevent osteoporosis. We hypothesize that risedronate may also be effective in prostate cancer patients treated with LHRH agonists.
IV bisphosphonates have proven effective in treating bone loss in prostate cancer patients treated with LHRH agonists. However, it is yet to be determined if an oral bisphosphonate such as risedronate could offer the same benefits.
Study Started
Jan 31
Primary Completion
Jan 31
Study Completion
Feb 28
Last Update
Feb 03

Drug risedronate

risedronate 35mg tablet, weekly for 12 months

  • Other names: Actonel

Drug risedronate

35mg weekly

  • Other names: Actonel

Drug Control

risedronate-matched placebo weekly

risedronate Active Comparator

placebo Placebo Comparator


Inclusion Criteria:

Patients over 18 years of age.
Histologically confirmed diagnosis of prostate cancer without metastases.
Patient must have negative bone scan to rule out bone metastases.
Patient for whom androgen deprivation therapy with leuprolide acetate is indicated for at least 1 year.
Eastern Cooperative Oncology Group (ECOG) score of 0 - 2.
Study medication must be started within 3 months of initiation of ADT.
Signed written informed consent.

Exclusion Criteria:

Prior ADT (greater than 3 months).
History of treatment with calcitriol or bisphosphonates.
Suppressive doses of thyroxine within the previous year.
Concomitant or prior history of long-term treatment (greater than or equal to 3 months) with systemic glucocorticoids.
Evidence of any of the following conditions per subject self-report or chart review:

Current hyper- or hypothyroidism (stable on thyroid replacement therapy is allowed, if TSH is within normal reference range).

Paget's disease, Cushing's disease, hyperprolactinemia, chronic liver disease. Unstable systemic disease including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months before randomization.

Major surgery or significant traumatic injury occurring within 1 month prior to randomization.

Known hypersensitivity to leuprolide acetate or any of the components found in Eligard
Any concurrent condition that would make it undesirable, in the physician's opinion, for the subject to participate in the study or would jeopardize compliance with the protocol.
No Results Posted